| Literature DB >> 33172208 |
Shintaro Yamada1, Seitaro Nomura1.
Abstract
Single-cell RNA sequencing (scRNA-seq) technology is a powerful, rapidly developing tool for characterizing individual cells and elucidating biological mechanisms at the cellular level. Cardiovascular disease is one of the major causes of death worldwide and its precise pathology remains unclear. scRNA-seq has provided many novel insights into both healthy and pathological hearts. In this review, we summarize the various scRNA-seq platforms and describe the molecular mechanisms of cardiovascular development and disease revealed by scRNA-seq analysis. We then describe the latest technological advances in scRNA-seq. Finally, we discuss how to translate basic research into clinical medicine using scRNA-seq technology.Entities:
Keywords: cardiomyocyte; cardiovascular development; cardiovascular disease; heart; single-cell RNA sequencing
Year: 2020 PMID: 33172208 PMCID: PMC7664385 DOI: 10.3390/ijms21218345
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Summary figure of single-cell RNA-sequencing in the heart.
Single-cell RNA sequencing in the heart.
| Species | Vivo / Vitro | Age | Cells or Nuclei | Model | Device | Number of Cells for Analysis | Findings | Ref. |
|---|---|---|---|---|---|---|---|---|
| mouse | vivo | fetus | cells from whole heart | healthy development | IFC system | 2233 cells | chamber-specific genes in the embryonic mouse heart | [ |
| fetus | cells from whole heart | healthy development and | Chromium | 73,926 cells | Hand2 is a specifier of outflow tract cells | [ | ||
| fetus | cells from whole heart | healthy development and | Chromium | 3600 cells | lncRNA Hand2os1/Uph regulates Hand2 | [ | ||
| fetus | cells from whole heart and other 7 organs | healthy development | mouth pipette | 1819 cells | mutual interactions between epithelial and mesenchymal cells | [ | ||
| fetus | healthy development and | FACS | 598cells | Mesp1 is required for the exit from the pluripotent state | [ | |||
| fetus | healthy development | FACS | 1231 cells | Cxcr2 regulates chemotaxis during development | [ | |||
| fetus | cells from cardiac conduction system | healthy development | Chromium | 22,462 cells | transcriptional profiles of cardiac conduction system | [ | ||
| fetus | cells from cardiac outflow tract | healthy development | Chromium | 55,611cells | cellular transitions in cardiac outflow tract | [ | ||
| fetus ~ neonate | cells from whole heart | healthy development | IFC system | >1200 cells | temporal and chamber-specific markers during development | [ | ||
| neonate | nuclei from whole heart | healthy development and pediatric mitochondrial cardiomyopathy | Chromium | 15,083 nuclei | heterogeneity of various cell types | [ | ||
| neonate | cells from left ventricles | healthy development | ICELL8 | 4231 cells | transcriptomes of mono- or multi-nucleated cardiomyocytes are highly similar | [ | ||
| neonate ~ juvenile | cells from aortic valve and mitral valve | healthy development | Drop-seq | 2840 cells | Interstitial cell subpopulations undergo changes in gene expression during development | [ | ||
| neonate, adult | cells from ventricles | healthy, I/R and MI | FACS | 1939 cells | Cycling CMs are few adult mouse | [ | ||
| mouse | vivo | adult | cells from whole heart | healthy condition and ischemia reperfusion | FACS | 935 cells | Ckap4 is a modulator of fibroblasts activation | [ |
| adult | cells from whole heart | healthy and TAC | ICELL8 | 11,492 cells | Macrophage activation is a key factor of hypertrophy | [ | ||
| adult | cells from left ventricles | healthy development | ICELL8 | 2497 cells | Fibroblast regulates CM maturation | [ | ||
| adult | CMs from ventricles | healthy and TAC | ICELL 8 | <1015 cells | heterogeneity among CMs after TAC | [ | ||
| adult | CMs from whole heart | healthy and TAC | manual pickup | 396 cells | p53 induces molecular and morphological remodeling | [ | ||
| adult | nuclei from whole heart | healthy aging | Chromium | 27,808 nuclei | heterogeneity of fibroblasts with aging | [ | ||
| adult | nuclei from ventricles | healthy and MI | Chromium | 31,542 nuclei | dedifferentiation in cycling CMs after MI | [ | ||
| adult | nuclei of CMs from left ventricles | healthy and TAC | IFC system | 243 nuclei | lincRNA regulates dedifferentiation and cell cycle genes | [ | ||
| adult | cells from sinus node | healthy pacemaking | Chromium | 5357 nuclei | Membrane clock underpins pacemaking | [ | ||
| adult | non-CMs | healthy and MI | Chromium | 13,331 cells | transcriptome changes of non-CMs after MI | [ | ||
| adult | fibroblasts | healthy and MI | IFC system | 104 cells | transcriptome changes of fibroblast after MI | [ | ||
| adult | endothelial cells | healthy and MI | Chromium | 28,598 cells | Plvap regulates endothelial proliferation | [ | ||
| neonate, adult | neonatal CMs, and neonatal and adult fibroblasts | healthy development | ICELL8 | 1580 cells | Fibroblast regulates CM maturation | [ | ||
| human | vitro | hiPSC-CMs | differentiation | Chromium | 43,168 cells | Hopx is a key regulator of CM maturation | [ | |
| hiPSC-CMs | differentiation | Chromium | 10,376 cells | ISL1, NR2F2, TBX5, HEY2, or HOPX are makers of hiPSC-CMs | [ | |||
| hiPSC-CMs | differentiation | IFC system | 43 cells | ISL1, NR2F2, TBX5, HEY2, or HOPX are makers of hiPSC-CMs | [ | |||
| CMs derived from embryonic stem cells | differentiation | FACS | 366 cells | LGR5 is a marker of cardiac progenitors in embryonic outflow tract | [ | |||
| hiPSC-CMs | differentiation | Drop-seq | 23,554 cells | the comparison with DroNc-seq | [ | |||
| nuclei of hiPSC-CMs | differentiation | DroNc-seq | 24,318 nuclei | Inclusion of reads from intronic regions increases the sensitivity | [ | |||
| epicardium hiPSC-CMs | differentiation | FACS | 232 cells | BNC1 regulates cell heterogeneity | [ | |||
| CMs reprogrammed from human fibroblasts | differentiation | IFC system | 704 cells | cell fate transitions during reprogramming | [ | |||
| human | vivo | fetus | cells from free wall | healthy development | mouth pipette | 3842 cells | Atrial and ventricular CMs acquires distinct features early in heart development | [ |
| fetus | cells from whole heart | healthy development | Chromium | 4026 cells | cell atlas of the developing human heart | [ | ||
| fetus | cells from whole heart | healthy development | FACS | 458 cells | LGR5 is a marker of cardiac progenitors in embryonic outflow tract | [ | ||
| fetus | cells from whole heart | healthy and autoimmune-associated congenital heart block | Chromium | 17,747 cells | heterogeneous interferon responses in congenital heart block heart | [ | ||
| adult | cells from whole heart | healthy, HF and functional recovery from HF after treatment with LVAD | ICELL8 | 21,422 cells | CM contractility and metabolism are prominent aspects that are correlated with changes in heart function. | [ | ||
| adult | CMs from left ventricles | healthy and DCM | manual pickup | 411 cells | heterogeneity in DCM CMs | [ | ||
| adult | nuclei from whole heart | healthy | DroNuc-seq | 1491 nuclei | the usefulness of DroNc-seq in adult human CMs | [ | ||
| adult | nuclei from CMs | healthy and DCM | IFC system | 116 nuclei | lincRNA regulates dedifferentiation and cell cycle genes | [ |
CMs, cardiomyocytes; hiPSC-CMs, human induced pluripotent stem cells-derived cardiomyocytes; I/R, ishchemia/reperfusion; DCM, dilated cardiomyopathy; MI, myocardial infarction; TAC, transverse aortic constriction; HF, heart failure; LVAD, left ventricular assist device; FACS, fluorescence-activated cell sorting; IFC, integrated fluidic circuit.